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Abstract
Background: Atrial fibrillation (AF) is a common arrhythmia that causes numerous visits to emergency departments
(ED). The aim of the FinFib2 study was to evaluate whether treatment of patients with AF in ED is consistent with
the contemporary European Society of Cardiology (ESC) management guidelines. Here we report the results of
antiarrhythmic drug therapy (AAD) in ED.
Methods: All patients within the two-week study period whose primary reason for the ED visit was symptomatic
AF were included into this prospective multicentre study. Comprehensive data on factors contributing to the
treatment of AF were collected, including a data of previous use of ADDs, and changes made for them during a
visit in ED.
Results: The study population consisted of 1013 consecutive patients (mean age 70 ± 13 years, 47.6% female). The
mean European Heart Rhythm Association (EHRA) symptom score was 2.2 ± 0.8. Rhythm control strategy was opt for
498 (63.8%) and 140 (64.5%) patients with previously and newly diagnosed AF, respectively. In patients with previously
diagnosed AF the most frequently used AAD was a beta blocker (80.9%). Prior use of class I (11.4%) and III (9.1%) AADs
as well as start or adjustment of their dosage (7.4%) were uncommon. Most of the patients with newly diagnosed AF
were prescribed a beta blocker (71.0%) or a calcium channel antagonist (24.0%), and only two of them received class I
or class III AADs.
Conclusions: Our data demonstrated that in patients presenting to the ED with recurrent symptomatic AF and aimed for
rhythm control strategy, the use of class I and class III AADs was rare despite ESC guideline recommendations. It is possible
that early adaptation of a more aggressive rhythm control strategy might improve a quality of life for symptomatic patients
and alleviate the ED burden associated with AF. Beta blockers were used by majority of patients as rate control therapy
both in rate and rhythm control groups.
Trial registration: NCT01990105. Registered 15 November 2013.
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Background
Atrial fibrillation (AF) is the most common sustained
arrhythmia [1]. Given the predicted increase in the inci-
dence of AF it has been estimated that in 2030 there will
be 14–17 million patients with AF in Europe [2–4].
Consequently, the amount of AF related visits to the
emergency departments (ED) is likely to rise extensively
in near future [5].
Emergency departments play a key role in management
of AF [6]. In patients with acute AF the decision between
rhythm and rate control is done in the ED. The severity of
symptoms related to AF is the main factor in selection of
the treatment strategy [7]. Age, presence of structural
heart disease and other co-morbidities, the type of AF and
contraindications to antiarrhythmic drugs (AAD) should
also be taken into account when evaluating the need and
reasonability of cardioversion, and how to prevent
recurrent AF episodes [8]. The efficacy and safety of beta
blockers and calcium channel antagonists are well
established in acute and long-term rate control [9]. Rate
control therapy should consider for all patients with
AF if needed, both in a rate and a rhythm control
strategies [10, 11]. In a rhythm control strategy,
additionally class I and III AADs are recommended
to maintain sinus rhythm [12–17]. Regardless of the
chosen treatment strategy the need of oral anticoagulation
(OAC) along with risk factors for thromboembolic com-
plications and bleeding must be evaluated [10, 11].
The results of previous studies indicate that there is
large variation in the management of AF in the ED
[18, 19]. The FinFib2 study was designed to evaluate
whether the treatment of patients with symptomatic
AF in the ED is in line with the European Society of
Cardiology (ESC) treatment guidelines valid at the
study period 2013 [10, 11]. We report real life data
on the selection of the treatment strategy, symptoms
and risk factors of AF, and use of antiarrhythmic
medication in these patients.
Methods
Study design and patient population
This prospective snapshot study was conducted in 35
EDs around Finland. There were a large variation of size
and facilities of EDs; units from small heath care centers
to big university hospitals were participating. Finland is
divided into five university hospital districts, and pa-
tients from all of them were enrolled in order to avoid
any bias due to geographical differences. All patients
whose primary reason for the ED visit was symptomatic
AF during a two-week study period (November 11–23,
2013) were included.
Data on concomitant diseases, risk factors for AF,
and a history of thromboembolic complications, treat-
ment strategy, and use of antiarrhythmic medication
was collected using predefined internet based case
report form. A rhythm control strategy means a phy-
sician’s aim to maintain a sinus rhythm. A rate con-
trol strategy means a physician’s decision to accept a
permanent AF. Symptoms associated to AF were
ranked using European Heart Rhythm Association
(EHRA) score [10] (Fig. 1). Antiarrhythmic drugs
were classified according to the Vaughan Williams
classification (Table 1).
A data of prior use and changes made for AADs in ED
were collected. A physician in ED made an independent
decision to choose a rate control strategy or a rhythm
control strategy for each patient. We evaluated the use
of AAD therapy during an ED visit to support that
decision; if the rhythm control was chosen, were a class
I or III AAD started or a dosage of these drugs changed.
We also evaluated a use of rate control drugs (beta and
calcium channel blockers) for all patients, both in a rate
and a rhythm control groups.
Statistical analysis
The data were analysed using IBM SPSS Statistics
software package version 22 (IBM SPSS Inc., Armonk,
NY, USA). Missing data values were excluded from the
statistical analysis. Continuous variables are expressed as
mean ± standard deviation and compared with inde-
pendent variables t-test or Mann-Whitney U-test when
appropriate. Categorical variables are expressed as num-
bers and percentages and compared by Fisher’s exact
test. All tests were two-sided and a P value of <0.05 was
considered statistically significant.
Results
Baseline characteristic of the study population
A total of 1013 consecutive patients with symptomatic AF
were enrolled into the study. In 217 (21.4%) patients AF
was diagnosed for the first time in the ED, whereas 780
(77.0%) patients had recurrent AF. The mean age of the
patients was 70.0 ± 13.1 years (19–103 years) - 67.7% of
them were 65 years or older, and 39.5% were 75 years or
older. Slightly less than half of them (47.6%) were female.
The most common underlying diseases were hypertension
(65.0%), dyslipidaemia (43.5%), coronary artery disease
(23.2%), and diabetes (21.1%) (Table 2).
The mean EHRA score was 2.2 ± 0.8. The most fre-
quent symptom was palpitation (620 patients, 61.2%).
Other AF related symptoms included dyspnoea (270 pa-
tients, 26.7%), dizziness (197 patients, 19.4%), and chest
pain (125 patients, 12.3%). Eighteen patients (1.8%) had
had syncope. Almost half of the patients with previously
diagnosed AF (354 patients, 45.4%) had had at least one
visit to the ED because of AF within the preceding
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12 months. For these patients, the mean number of prior
ED admissions per patient was 2.7 ± 3.6 (range 1–30).
Prior antiarrhythmic therapy
Most of the patients (85.3%) with previously diagnosed
AF were using antiarrhythmic medication for rhythm or
rate control when admitted to the ED. Beta blockers
were used by 631 (80.9%), digoxin by 72 (9.2%), and ver-
apamil or diltiazem by 23 (2.9%) of these patients. Class
I AADs were used by 89 (11.4%) patients. The majority
of them were using flecainide (87 patients, 11.2%), and
two patients were on quinidine (0.3%). The other AADs
included amiodarone (26 patients, 3.3%), dronedarone
(30 patients, 3.8%) and sotalol (15 patients, 1.9%).
Treatment strategy and initial management in the ED
In patients with previously diagnosed AF the rhythm
disorder was paroxysmal in 282 (36.5%), persistent in
298 (38.7%) and permanent in 191 (24.8%) patients.
Rhythm control strategy was chosen by ED physicians in
498 of the 580 (85.9%) patients with paroxysmal or
persistent AF. Among them 287 and 62 patients
underwent successful acute electrical or pharmacological
cardioversion, respectively. Sinus rhythm restored spon-
taneously or an elective cardioversion were planned in
149 patients. The AADs used for pharmacological car-
dioversion included flecainide (17 patients), amiodarone
(7 patients), vernakalant (6 patients), and a beta blocker
or digoxin (32 patients).
There were 217 patients with newly diagnosed AF in the
study population. The rhythm control strategy was chosen
for 140 (64.5%) of them. Normal sinus rhythm resumed
spontaneously in 51 patients. Electrical or pharmacological
cardioversion was performed in 43 and 21 (beta blocker 17,
digoxin 1, flecainide 3, amiodarone 1) patients, respectively.
An elective cardioversion was planned for 25 patients.
a
b
Fig. 1 Classification of AF related symptoms according to the European Heart Rhythm Association (EHRA) score in patients with prior (n = 780)
and newly diagnosed AF (n = 217) (a) and in patients with rhythm control (n = 659) and rate control strategy (n = 336) (b). EHRA 1 = no
symptoms, EHRA 2 = mild symptoms (normal daily activity not affected), EHRA 3 = severe symptoms (normal daily activity affected), EHRA
IV = disabling symptoms (normal daily activity discontinued)
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The patients in whom rate control strategy was chosen
were significantly older than those with rhythm control
strategy (78.6 ± 10.1 vs. 65.7 ± 12.4 years, P < 0.001).
The EHRA score was significantly higher among patients
with rhythm control strategy (2.3 ± 0.7 vs. 2.0 ± 0.9,
P < 0.001), whereas the CHA2DS2VASc (4.4 ± 1.8 vs.
2.4 ± 1.9, P < 0.001) and HAS-BLED (2.6 ± 1.2 vs.
1.5 ± 1.1, P < 0.001) scores were higher among those
with rate control strategy (Table 2).
Antiarrhythmic drug therapy at discharge
At discharge from the ED 625 (80.1%) patients with
prior AF diagnosis were prescribed beta blocker medi-
cation. Despite recurrent AF symptoms a change in
antiarrhythmic medication was done only in 97 of
these patients (12.4%). Class I or III antiarrhythmic
medication was started or the dosage of the drug
used was adjusted in 37 (7.4%) of the patients with
previous AF diagnosis and rhythm control strategy.
The reasons for the changes in AAD therapy included
inadequate antiarrhythmic efficacy (68 patients), adverse
effects (11 patients), change into rate control strategy (19
patients) and lack of compliance (1 patient).
In patients with newly diagnosed AF a beta blocker
was prescribed for 154 (71.0%), a calcium channel antag-
onist for 52 patients (24.0%), and digoxin for 8 patients
(3.7%). Amiodarone was started for 2 patients, but no
class I drugs were prescribed for the patients with newly
diagnosed AF.
Discussion
The results of the FinFib2 study demonstrated that
despite recurrent symptoms and ESC guideline recom-
mendations prior use and initiation of class I and class
III antiarrhythmic medication are rare in patients
presenting to the ED with symptomatic AF (Fig. 2).
At admission to the ED class I or III antiarrhythmic
drugs were used only by 20.5% of the patients with
prior AF diagnosis, and at discharge 36.5% of the pa-
tients in the rhythm control group were prescribed
class I or III antiarrhythmic medication. With regard
to the current guidelines recommending execution of
“upstream” therapy and use of class I and III antiar-
rhythmic drugs in the early stage of the disease, these
numbers appear low [20, 21]. In patients with highly
symptomatic AF active rhythm control strategy is ex-
pected not only to improve the quality of life, but
also to reduce ED burden associated with AF.
After cardioversion, the likelihood of AF recurrences is
highest during the following weeks [22]. It has been
shown that 56% of the patients presenting to the ED
with symptomatic AF will have a repeat ED visit due to
Table 1 Antiarrhythmic drugs according to the Vaughan Williams classification. None of the patients received drugs which are
presented in parenthesis




Sodium channel blockade with intermediate
association/dissociation and potassium channel
blockade
Contraindicated in patients with structural heart diseases
IB (Lidocaine)
(Mexiletine)
Sodium channel blockade with rapid association/
dissociation
Not indicated for AF
IC Flecainide
(Propafenone)
Sodium channel blockade with slow association/
dissociation











Beta adrenergic receptor blockade Can be used also in patients with structural heart disease






Amiodarone and dronedarone have also class
I, II and IV activity
Sotalol has also class II activity
Vernakalant blocks sodium and potassium
channels in atria but not in ventricles
Dronedarone is contraindicated in severe heart failure and
permanent AF
Extra cardiac adverse events (e.g., liver and pulmonary toxicity
and thyroid dysfunction) are common with amiodarone
Vernakalant is available only for acute intravenous use
IV Verapamil
Diltiazem
Calcium channel blockade Should be avoided in patients with congestive heart failure
Others Digoxin Variable mechanisms May have adverse effect on the prognosis of patients with AF
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Table 2 Clinical characteristics of the patients with symptomatic atrial fibrillation (AF) on admission to the emergency department








Patients 1013 659 (65.1) 336 (33.2)
Previously diagnosed AF 780 498 (63.8) 261 (33.5)
Newly diagnosed AF 217 140 (64.5) 71 (32.7)
Age 70.0 ± 13.1 (19–103) 65.7 ± 12.4 78.6 ± 10.1 < 0.001
Female 482 (47.6) 267 (40.5) 205 (61.0) < 0.001
Congestive heart failure 176 (17.4) 57 (8.6) 115 (34.2) < 0.001
Hypertension 658 (65.0) 395 (59.9) 251 (74.7) < 0.001
Diabetes 214 (21.1) 116 (17.6) 95 (28.3) < 0.001
Stroke 81 (8.0) 37 (5.6) 41 (12.2) < 0.001
Transient ischemic attack 53 (5.2) 21 (3.2) 32 (9.5) < 0.001
Other thromboembolic events 24 (2.4) 8 (1.2) 15 (4.5) 0.003
Coronary artery disease 235 (23.2) 106 (16.1) 122 (36.3) < 0.001
Previous myocardial infarction 126 (12.4) 55 (8.3) 66 (19.6) < 0.001
Atherosclerosis 39 (3.8)) 15 (2.3) 24 (7.1) < 0.001
Dyslipidaemia 441 (43.5) 273 (41.4) 161 (47.9) 0.042
Ongoing or ex-smoking 254 (25.1) 174 (26.4) 75 (22.3) 0.809
Valvular disease 128 (12.6) 63 (9.6) 65 (19.3) < 0.001
Thyroid dysfunction 112 (11.1) 66 (10.0) 45 (13.4) 0.136
Lung disease 135 (13.3) 72 (10.9) 61 (18.2) 0.002
Renal insufficiency 100 (9.9) 27 (4.1) 70 (20.8) < 0.001
Liver insufficiency 18 (1.8) 7 (1.1) 11 (3.3) 0.021
Anaemia 103 (10.2) 39 (5.9) 62 (18.5) < 0.001
History of major bleeding 34 (3.4) 16 (2.4) 18 (5.4) 0.026
Echocardiography 508 (50.1) 353 (53.6) 152 (45.2) 0.015
EHRA score 2.2 ± 0.8 2.3 ± 0.7 2.0 ± 0.9 < 0.001
CHA2DS2-VASc score 3.1 ± 2.1 2.4 ± 1.9 4.4 ± 1.8 < 0.001
HAS-BLED score 1.9 ± 1.2 1.5 ± 1.1 2.6 ± 1.2 < 0.001
Fig. 2 The use of antiarrhythmic drugs among patients with previously diagnosed AF (n = 780) at admission to the ED (black column) and at
discharge (light grey column)
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AF recurrence within a year [18]. This was reflected in
our study population by the high number of previous
visits to ED. In patients with acute AF normal sinus
rhythm can be effectively restored by electrical or pharma-
cological cardioversion [20]. However, in rhythm control
strategy cardioversion alone is hardly ever enough but a
physician should always try to find a way to prevent AF
recurrences. In our survey, a class I or III antiarrhythmic
medication was started or the dosage was optimized as a
part of a rhythm control strategy only in about 7% of the
patients with a previously diagnosed AF. It is well estab-
lished that early intervention is crucial for the long-term
efficacy of antiarrhythmic drugs and catheter ablation.
Therefore, decision to start a class I or III antiarrhythmic
medication should be done in the ED if structural heart
disease has been excluded by recent examinations and
clinical history. Echocardiography plays a key role in diag-
nosis of many cardiac diseases and selection of AF treat-
ment strategy. In our study, it had been done earlier for
half of the patients.
However, as the rhythm control strategy has not dem-
onstrated a mortality benefit compared to the rate control
strategy in large studies, it should be not used for all pa-
tients with AF [23–25]. In our study, patients in the rate
control group were older, had more concomitant diseases,
and a lower symptom score.
A rate control therapy should be considered for all
patients with AF despite of a treatment strategy, if a
heart rate during AF is rapid. In this study popula-
tion, a rate control therapy was used by most of the
patients. In line with the results of previous studies,
about 80% of the patients in our study were using
beta blockers [26]. The efficacy of beta blockers to re-
duce ventricular rate in patients with AF is well
established, but their efficacy in preventing AF recur-
rences is only modest [22, 27].
According to the contemporary AF management
guidelines class I agents should be the drug of choice for
rhythm control in patients with lone AF. Despite this,
significantly less effective beta blocker medication was
used as a first line therapy in most of these patients, and
none of them received class I antiarrhythmic medication
after a first documented AF episode.
The facilities to treat patients with AF vary be-
tween different EDs in Finland. In small heath care
centers it’s not possible to make an electrical cardio-
version, and a patient has to be sent to a bigger
unit. In smaller EDs physicians experience to use
AADs might not be as good as in bigger units. In
Finland, we are going towards bigger ED units in
near future, which is expected to improve the quality
of rhythm control therapy of patients with AF, and
also improve acute collaboration between ED physi-
cians and cardiologists.
Limitations
This study provided a snapshot of the management of
patient with AF in an emergency care setting. There-
fore, no follow-up data are available. For example,
many patients were referred to a cardiologist but the
results of the further examinations and therapies were
not available. Likewise, it was not possible to assess a
rationality of all individual treatment decisions; there-
fore we assessed a treatment decisions the physicians
made after choosing a treatment strategy. Finally, the
results of this study may not be directly extrapolated
to different health care systems. In Finland all inhabi-
tants are covered by national health insurance and
patients need to pay only a nominal fee for ED visits
and hospitalization.
Clinical implications
ED physicians play a key role in treatment of acute AF.
We have previously shown that patients with high risk
of thromboembolic complications were recognized well
by the ED physicians, and oral anticoagulation therapy
(OAC) was prescribed for the majority of these patients
[28]. The results of the current analysis indicate that
rhythm control therapy is not understood and executed
as well as OAC therapy. According to contemporary
ESC clinical practice guidelines rhythm control strategy
should be considered for patients with recurrent epi-
sodes of symptomatic AF [10, 11]. On the other hand,
rate control strategy is a feasible choice in patients with
mild symptoms. In many cases the treatment strategy
can be selected and implemented in the ED. In our study
the factors favouring a rate control strategy included
older age, concomitant diseases and mild/moderate
symptoms.
Early adaptation of an aggressive rhythm control strat-
egy is likely to alleviate the ED burden associated with
symptomatic AF. In order to be able to select the most
appropriate antiarrhythmic therapy for a given patient
the ED physician should evaluate the symptoms of the
patient and take thorough clinical history. He/she should
have enough information on the results of prior cardiac
examinations (e.g., electronic nationwide patient re-
cords) and knowledge of the key features of the antiar-
rhythmic drugs (Table 1). Class I AADs have been
shown to be safe and effective in patients with lone AF
but contraindicate in patients with structural heart dis-
ease [29]. Hence, if no data on echocardiographic and
other cardiac examination are available the patient
should be referred to cardiologist for elective evaluation
or rather a cardiologic consultation should be readily
available in ED. Structured local instructions for
treatment of AF patients and close collaboration with
cardiologists play a key role in this process.
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Conclusions
Current survey is one of the largest studies evaluating
AF treatment strategy and antiarrhythmic therapy in an
emergency care setting. Our data indicate that rhythm
control therapy is not understood and executed ad-
equately in the ED. That is, in contrast to contemporary
AF management guidelines a beta blocker was by far the
most commonly used AAD and use of more effective
drugs was rare also in symptomatic patients in rhythm
control group.
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